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Cryptosporidium parvum is a zoonotic apicomplexa-protozoan pathogen that 12 
causes gastroenteritis and diarrhoea in mammals worldwide. The organism is 13 
transmitted by ingestion of oocysts, which are shed in faeces, and completes its 14 
lifecycle in a single host.1 C. parvum is ubiquitous on dairy operations worldwide 15 
and is one of the leading causes of diarrhoea in calves on these farms.2,3 Here, for 16 
the first time, we describe the antibody response in a large group of cows to a 17 
recombinant C. parvum oocyst surface protein (rCP15/60) vaccine and the 18 
antibody response in calves fed rCP15/60-immune colostrum produced by these 19 
vaccinated cows. Results of recent genotype surveys indicate that calves are the 20 
only major reservoir for C. parvum infections in humans.4 Human C. parvum 21 
infections are particularly prevalent and often fatal in neonates in developing 22 
countries and to immunocompromised people, such as AIDs patients.4 Drug 23 
therapy against cryptosporidiosis is limited and not wholly efficacious in either 24 
humans or calves5, making development of an effective vaccine of paramount 25 
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importance. To date, there is no commercially available effective vaccine against 1 
C. parvum, although passive immunization utilizing different zoite surface 2 
(glyco)proteins has showed promise.6-9 All cows we vaccinated produced an 3 
antibody response to the rCP15/60 vaccine and the magnitude of response 4 
correlated strongly with the subsequent level of antibody in their colostrum. All 5 
calves fed rCP15/60-immune colostrum showed a dose-dependent absorption of 6 
antibody. Our results demonstrate that vaccination of cows with rCP15/60 7 
successfully induces antibodies against CP15/60 in their serum and colostrum and 8 
that these antibodies are then well absorbed when fed to neonatal calves. With 9 
further research, this C. parvum vaccine may well be a practical method of 10 
conferring passive protection to calves against cryptosporidiosis. Furthermore, a 11 
specifically targeted immune-colostrum may be valuable in protection and 12 
treatment of immunocompromised human patients with cryptosporidiosis. 13 
 14 
The genus Cryptosporidium is comprised of to date, 20 species, with various 15 
host-adaptations and has been found infecting 155 species of mammals. Arguably the 16 
most important of these Cryptosporidium spp. are C. hominis, which is host-adapted to 17 
humans, and C. parvum which infects many mammals and is an important 18 
zoonosis.1,4,10-12 The life cycle of Cryptosporidium spp. results in production of an 19 
encysted stage (oocyst), which is passed in the faeces of the host. The oocyst is then 20 
transmitted by the faecal-oral route via contaminated water, food, fomites by direct 21 
contact with human or animal faeces. Cryptosporidiosis is the clinical syndrome of 22 
fever, diarrhoea, vomiting, abdominal pain, large volumes of fluid loss.1 In humans, the 23 
species and subtypes of Cryptosporidium, source of infection and type of transmission 24 
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vary geographically.10 Cryptosporidiosis (mainly due to C. hominis) is an important 1 
cause of morbidity and mortality of children in developing countries, through diarrhoea 2 
with subsequent dehydration and death.13,14 In the developed nations, C. parvum most 3 
often infects immunosuppressed people such as AIDs patients but cryptosporidiosis 4 
outbreaks in the general immune-competent population have occurred due to 5 
contamination of a water supply.10,14-16 The largest of these outbreaks was in Milwaukie, 6 
Wisconsin in 1993 with approximately 403,000 people affected.17 Data collected via the 7 
National Dairy Heifer Evaluation Project indicated that Cryptosporidium spp. were 8 
detected in over 90% of North American dairy operations.18 C. parvum is one of the 9 
leading causes of diarrhoea in neonatal dairy calves and as such, contributes to 10 
substantial economic losses.2,3 11 
We are developing a C. parvum vaccine for use in pregnant cows to provide 12 
passive protection to the calf, via colostrum as an aid to prevention of diarrhoea caused 13 
by C. parvum. Development of vaccines centres round interruption of the lifecycle of C. 14 
parvum via antibodies that target critical surface exposed proteins and hence 15 
interrupting replication and survival of the organism. Over the past 20 years, some 16 
research groups have published data on passive immunization and immunotherapy 17 
against C. parvum in mice, goats and cattle using different zoite surface (glyco)proteins 18 
expressed during, and involved in, invasion and infection of host epithelial cells.6-9, 19 19 
However, a successful vaccine has yet to emerge.  20 
The 15 kDa 123 amino acid antigen of C. parvum designated CP15/60 21 
(GenBank Accession No. L34568) was identified by Jenkins and Fayer.20 CP15/60 is 22 
expressed by the infective sporozoite and merozoite stages on the oocyst surface and is 23 
also associated with internal structures.19 The gene encoding the CP15/60 has been 24 
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cloned, and expressed as a recombinant protein (rCP15/60).20 We vaccinated pregnant 1 
19 – 26 month-old heifers with rCP15/60 in a water-in-oil adjuvant or an adjuvant 2 
placebo. All heifers had low (< 8) CP15/60 antibody titres prior to vaccination. 3 
rCP15/60 vaccinated heifers had a significantly higher serum and colostrum titres to 4 
CP15/60 compared to control heifers at all 3 measured time points after vaccination (P 5 
< 0.0001, n = 40) (Table 1). The serum CP15/60 antibody titre at its highest point (day 6 
42 after vaccination) had a strong positive correlation with the CP15/60 antibody titre in 7 
the colostrum (r = 0.82, P < 0.0001, n = 20 (Fig. 1).  8 
Forty female and male Holstein dairy calves, unrelated to the vaccinated or 9 
control heifers, were randomly assigned and fed either rCP15/60-immune colostrum or 10 
control colostrum produced by the aforementioned vaccinated heifers. CP15/60 11 
antibody titres were low (< 8) in all calves prior to colostral administration. In order to 12 
assess endogenous humoral immune response in the face of natural infection, 13 
specifically to CP15/60 antibodies in the face of natural infection, we administered 104 14 
viable C. parvum oocysts orally to control calves at 12 hours of age. We found that 15 
calves administered rCP15/60-immune colostrum had significantly higher serum 16 
CP15/60 antibody titres at 48 hours, 96 hours and 21 days post colostral ingestion 17 
compared to calves administered the control colostrum (P < 0.0001, n = 39) (Table 2). 18 
Of the time points tested, calf serum CP15/60 antibody titre peaked at 48 hours after 19 
colostral ingestion. In the immune-colostrum fed calves, serum CP15/60 antibody titre 20 
at all three time points measured post ingestion was strongly correlated with the 21 
CP15/60 antibody titre in the actual colostrum aliquot (at 48 hours r = 0.83, P < 0.0001, 22 
at 96 hours r = 0.83, P < 0.0001, at 21 days, r = 0.78, P < 0.0001, n = 39 at all time 23 
points) (Fig. 2 a-c). This showed that the calves absorbed the colostrum well in a dose 24 
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dependent fashion. We confirmed that there was no significant difference in sex 1 
distribution or weight in the two groups of calves at enrolment in the study (birth) and 2 
thus these were not potential confounding factors (P = 0.6, n = 39).  3 
In addition to its importance as a zoonosis, it is the difficulty in control of 4 
Cryptosporidium spp. that emphasises the need for a successful vaccine. Eradication of 5 
of Cryptosporidium spp. from the environment is extremely difficult, as the infective 6 
oocysts are resistant to most disinfectants, can persist viable in the environment for 7 
many months. The infective oocysts are also very small (4 – 6 µm in diameter), evading 8 
many municipal water filtering strategies.1,4,15 Historically, drugs used to treat 9 
cryptosporidiosis have only been partially effective.5 Recently, the anti-protozoal agent 10 
nitazoxanide has been demonstrated to be efficacious in cryptosporidiosis in humans21 11 
and experimentally in calves22 but only when a normal immune response is present in 12 
the individual treated.23 There are no drugs effective against Cryptosporidium spp. 13 
licensed for use in the dairy industry in the USA although halofuginone (labelled for use 14 
in Europe and Canada) and paramomycin (labelled for use in Europe) have partial 15 
efficacy.24,25  16 
This is the first report of a CP15/60 vaccine against C. parvum tested on the 17 
cohort for which it is intended (i.e. vaccinated pregnant cattle with the immune-18 
colostrum fed to commercial dairy calves with a normal sex distribution). In 1999, 19 
Jenkins et al. administered rCP15/60-immune colostrum produced by vaccinated cows 20 
to mice and demonstrated a partial protection against intestinal C. parvum infection in 21 
these mice compared to controls. However, these cows were vaccinated in a non-22 
conventional manner by injection of recombinant plasmid DNA encoding the CP15/60 23 
antigen directly in to the mammary gland.26 We have shown that when administered the 24 
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CP15/60 vaccine, pregnant heifers successfully produce high levels of CP15/60 1 
antibody in their colostrum. The CP15/60 antibody is then reliably absorbed by calves 2 
from the colostrum. We did not see a significant increase in CP15/60 antibody titre in 3 
the control calves, despite infection with C. parvum. This confirmed that the CP15/60 4 
antibody titre rise in the vaccinate calves was due to administration of rCP15/60-5 
immune colostrum. The next stage in our work is to determine the minimum amount of 6 
antibody required to control disease due to C. parvum.  7 
If our CP15/60-immune colostrum is successful at preventing disease due to C. 8 
parvum, not only will it significantly reduce calf morbidity and mortality in the dairy 9 
industry but it may impact human disease control also. Since many cases of human 10 
cryptosporidiosis are zoonotic, most often from a bovine source,4,11,12 reduction in 11 
shedding of C. parvum by cattle may reduce the incidence of human cryptosporidiosis 12 
due to C. parvum.  Bovine colostrum has already been used as therapy for 13 
cryptosporidiosis in immunosuppressed patients and children with diarrhoea.27,28 14 
Specific immune bovine colostrum may provide more specific, targeted immunotherapy 15 
against Cryptosporidium spp.  16 
Methods  17 
Heifer vaccination. We vaccinated 46, 19 – 26 month-old pregnant heifers with 18 
rCP15/60 with a water-in-oil adjuvant or an adjuvant placebo. Six heifers either had 19 
inaccurate breeding dates or did not produce sufficient first milking colostrum to feed a 20 
calf and therefore were not used further in the study. Heifers were 180 to 210 days 21 
pregnant at the first vaccination, and were revaccinated 21 days later.  The heifers 22 
calved 32 to 63 days (median, 71 days) after the second vaccination. Colostrum from 23 
the first milking (> 4 L) was collected on the day of parturition, aliquoted, labelled by 24 
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heifer identification number and stored at -10°C until use. We defrosted the colostrum 1 
aliquots as needed in a hot water (85-90 °C) bath, immediately prior to feeding to the 2 
calves.  3 
Calves. Male and female Holstein calves weighing between 29.5 and 54.5 kg (65 - 120 4 
lbs) were enrolled at birth from a commercial dairy herd. The calves were delivered, 5 
handled and housed such as to minimize exposure to environmental pathogens, 6 
including any environmental C. parvum. Immediately prior to parturition, we washed 7 
the dam’s perineum and vulva with soap and warm water. We delivered each calf 8 
manually on to clean plastic sheeting so that no part of the calf made contact with the 9 
bedding or faeces and then brought the calf to an individual clean processing area. Each 10 
calf was identified with an ear tag number and a 5 mL blood sample was collected via 11 
jugular venipuncture for measurement of initial rCP15/60 titre. Calves were randomized 12 
to rCP15/60-immune colostrum or control colostrum, and fed 2 litres of the appropriate 13 
colostrum via oro-gastric tube feeder within 1 hour of birth. Calves were loose housed 14 
in individual box stalls bedded with wood shavings in a Biosecurity Level 2 facility at 15 
Cornell University. We fed a second 2 litres of either rCP15/60 immune colostrum or 16 
control colostrum 12 hours after birth via oro-gastric tube feeder. One hour after this 17 
second feeding, we administered 104 oocysts of C. parvum in 4 mLs of distilled water 18 
via an oesophageal tube feeder to the control calf group. Thereafter, we fed all calves 2 19 
litres of commercial milk-replacer twice daily from a bucket with free choice water 20 
available at all times. Calves were bled for serum prior to the first colostrum feeding 21 
and 48 hours, 96 hours, and 21 days after the feeding. We separated the serum and 22 
stored it at -80 °C prior to ELISA analysis.  23 
Cryptosporidium parvum oocyst purification. To obtain C. parvum oocysts for 24 
infection of the calves, we collected faeces from 7 – 14 day old C. parvum infected 25 
Holstein calves from a large commercial dairy farm in New York State, USA. We 26 
processed the faeces to obtain C. parvum oocysts by continuous flow differential 27 
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density flow as previously described.29 After a final Percoll purification step we washed 1 
the oocysts by centrifugation 3 times in cold distilled water at 2,100 g for 10 minutes to 2 
remove the Percoll, adjusted to a concentration of 1000 oocysts per mL with distilled 3 
water and stored at 4°C. Prior to inoculation into the calves, we assessed oocyst viability 4 
using a dye permeability assay.29 5 
ELISA. We used a competitive ELISA to determine serum and colostrum antibody 6 
titres to CP-15/60. ELISA plates were coated with purified rCP15/60 antigen, blocked 7 
and washed. Serial two-fold dilutions of test bovine sera and dilutions of positive and 8 
negative control sera were made on low binding dilution plates. The diluted serum 9 
samples were transferred to the coated plate and co-incubated with rabbit anti-CP15/60 10 
(the competitive serum). The plates were washed prior to incubation with horse radish 11 
peroxidise conjugated anti-rabbit serum. TMB (3,3’,5,5’-Tetramethylbenzidine) dye-12 
substrate was added to the wells and the plates then incubated. The colour reaction was 13 
stopped by the addition of acid and the optical densities read at 450 nm with a reference 14 
wavelength of 540 nm. The antibody titre was determined based on the reciprocal of the 15 
highest dilution showing approximately 30% inhibition of the competitive antibody. 16 
The values on each plate were adjusted based on the response of the positive control 17 
serum. 18 
Statistics. Using the Shapiro-Wilk test, we determined the data to be non-Gaussian. We 19 
used the Wilcoxon Rank Sum test to compare sets of continuous data (weight and 20 
antibody titres) for the two groups of calves (vaccinates and controls) and Fisher’s 21 
Exact test to analyse the dichotomous variable of sex. Associations between colostrum 22 
and serum antibody titres in both the cows and calves were analysed using Spearman’s 23 
Rank Correlation. When looking at the antibody titres over the 3 different time points, 24 
9 
 9
due to multiple comparisons within the same animal, a Bonferroni correction was used 1 
and hence alpha set at 0.017. For all other tests where multiple comparisons were not 2 
being made, alpha was set at 0.05. Data were anlyzed using Statistix 9.0 (Analytical 3 
Software, Tallahassee FL). 4 
This study was approved by the Institutional Animal Care and Use Committee (IACUC) 5 
at Cornell University. 6 
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Figure 1 CP15/60 antibody (Ab) titres in the serum (x axis) at day 42 post 10 
vaccination showed a strong correlation (Spearman’s Rank Correlation) with 11 
CP15/60 Ab titres in the colostrum at parturition (y axis) in heifers inoculated 12 
with the rCP15/60 C. parvum vaccine (r = 0.82, P< 0.0001). 13 
Figure 2 CP15/60 antibody (Ab) titre in the colostrum ingested (x axis) strongly 14 
correlated (Spearman’s Rank Correlation) with CP15/60 antibody (Ab) titre in 15 
the serum of the calves that received CP15/60 immune-colostrum at all three 16 
time points measured. a, 48 hours post colostral administration (r = 0.83, p < 17 
0.0001). b, 96 hours post colostral administration (r = 0.83, p < 0.0001). c, 21 18 
days post colostral administration (r = 0.78, p = 0.0001). 19 
20 
14 
 14
Table 1 CP15/60 antibody (Ab) titres post vaccination for all heifers 1 
 Median (range) 
CP15/60 
serum Ab titre 
at day 1 
Median (range) 
CP15/60 
serum Ab titre 
at day 42 
Median (range) 
CP15/60 
serum Ab titre,  
parturition 
Median (range) 
CP15/60 Ab 
titre, 1st 
colostrum 
Median (range) 
CP15/60 Ab 
titre, 2nd  
colostrum 
Heifers given 
rCP15/60   
(n = 20) 
2 
(< 2 – 8) 
128 
(16 – 1024) 
32 
(4 – 256) 
1024 
(256 –4096) 
512 
(64 – 2048) 
Heifers given 
placebo      
(n = 20) 
2 
(< 2 – 4) 
2 
(< 2 – 64) 
2 
(< 2 – 4) 
4 
(<2 – 16) 
2 
(<2 – 16) 
 2 
3 
15 
 15
Table 2 Serum CP15/60 antibody (Ab) titres for all calves  1 
 Median (range) 
CP15/60 Ab titre at 
birth (0 hours) 
Median (range) 
CP15/60 Ab titre at 
48 hours 
Median (range) 
CP15/60 Ab titre at 
96 hours 
Median (range) 
CP15/60 Ab titre at 
504 hours 
Calves fed 
CP15/60-immune 
colostrum (n = 19) 
< 2 
(< 2 – 8) 
128 
(8 – 512) 
128 
(8 – 512) 
128 
(2 – 256) 
Calves fed control 
colostrum (n = 20) 
< 2 
(< 2 – < 2) 
< 2 
(< 2 – < 2) 
< 2 
(< 2 – 2) 
< 2 
(< 2 – 128) 
 2 
 3 




